Hypertriglyceridemia in combination antiretroviral-treated HIV-positive individuals: Potential impact on HIV sensory polyneuropathy

AIDS

Volumn 25, Issue 2, 2011, Pages

  Banerjee, Sugato ^a   McCutchan, J Allen ^b   Ances, Beau M ^c   Deutsch, Reena ^d   Riggs, Patricia K ^d   Way, Lauren ^d   Ellis, Ronald J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

antiretroviral; HIV; sensory neuropathy; triglyceride

Indexed keywords

2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEINASE INHIBITOR; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; ANTIVIRAL THERAPY; ARTICLE; BODY HEIGHT; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SENSORY NEUROPATHY; TRIACYLGLYCEROL BLOOD LEVEL;

ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; HYPERTRIGLYCERIDEMIA; MALE; MIDDLE AGED; PERIPHERAL NERVOUS SYSTEM DISEASES; PREVALENCE; PROSPECTIVE STUDIES; QUALITY OF LIFE; RISK FACTORS; VIRAL LOAD;

EID: 78650869874     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328341dd68     Document Type: Article

References (27)

1. Ellis RJ RD, Clifford DB, McArthur JC, Simpson D, Alexander T, Gelman BB, Vaida F, et al. for the CHARTER Study Group. Continued high prevalence and adverse clinical impact of humanimmunodeficiency virus-associatedsensory neuropathy in the era of combination antiretroviral therapy: The CHARTER Study. Arch Neurol 2010; 67.
2. Bacellar H, Munoz A, Miller EN, Cohen BA, Besley D, Selnes OA, et al. Temporal trends in the incidence of HIV-1-related neurologic diseases: multicenter AIDS Cohort Study, 1985-1992. Neurology 1994; 44:1892-1900.
3. Ellis RJ, Marquie-Beck J, Delaney P, Alexander T, Clifford DB, McArthur JC, et al. Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy. Ann Neurol 2008; 64:566-572.
4. Tagliati M, Grinnell J, Godbold J, Simpson DM. Peripheral nerve function in HIV infection: clinical, electrophysiologic, and laboratory findings. Arch Neurol 1999; 56:84-89.
5. Childs EA, Lyles RH, Selnes OA, Chen B, Miller EN, Cohen BA, et al. Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology 1999; 52:607-613.
6. Cherry CL, Affandi JS, Imran D, Yunihastuti E, Smyth K, Vanar S, et al. Age and height predict neuropathy risk in patients with HIV prescribed stavudine. Neurology 2009; 73:315-320.
7. Evans SR, Clifford DB, Chen H, Schifitto G, Yeh T, Wu K, et al. HIV-associated peripheral neuropathy in the HAART era: results from AIDS Clinical Trials Group longitudinal linked randomized trials Protocol A5001. Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections; 8-11 February 2009; Montréal, Canada. Abstract 462.
8. Costa LA, Canani LH, Lisboa HR, Tres GS, Gross JL. Aggregation of features of the metabolic syndrome is associated with increased prevalence of chronic complications in type 2 diabetes. Diabet Med 2004; 21:252-255.
9. Sheth SG, Rao CV, Tselis A, Lewis RA. HIV-related peripheral neuropathy and glucose dysmetabolism: study of a public dataset. Neuroepidemiology 2007; 29:121-124.
10. Ances BM, Vaida F, Rosario D, Marquie-Beck J, Ellis RJ, Simpson DM, etal. Roleof metabolic syndrome componentsin HIV-associated sensory neuropathy. AIDS 2009; 23:2317-2322.
11. Banegas JR, Segura J, Sobrino J, Rodriguez-Artalejo F, de la Sierra A, de la Cruz JJ, et al. Effectiveness of blood pressure control outside the medical setting. Hypertension 2007; 49: 62-68.
12. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension 2005; 45:142-161. (Pubitemid 40066429)
13. Cuchel M, Schaefer EJ, Millar JS, Jones PJ, Dolnikowski GG, Vergani C, et al. Lovastatin decreases de novo cholesterol synthesis and LDL Apo B-100 production rates in combined-hyperlipidemic males. Arterioscler Thromb Vasc Biol 1997; 17:1910-1917.
14. Calza L, Manfredi R, Colangeli V, Pocaterra D, Pavoni M, Chiodo F. Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors. Curr HIV Res 2008; 6:572-578.
15. Tesfaye S, Chaturvedi N, Eaton SE, Ward JD, Manes C, Ionescu-Tirgoviste C, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005; 352:341-350.
16. Gonzalez-Duarte A, Robinson-Papp J, Simpson DM. Diagnosis and management of HIV-associated neuropathy. Neurol Clin 2008; 26:821-832; x.
17. Isomaa B, Henricsson M, Almgren P, Tuomi T, Taskinen MR, Groop L. The metabolic syndrome influences the risk of chronic complications in patients with type II diabetes. Dia-betologia 2001; 44:1148-1154.
18. Luciano CA, Pardo CA, McArthur JC. Recent developments in the HIV neuropathies. Curr Opin Neurol 2003; 16:403-409.
19. Chong PH, Boskovich A, Stevkovic N, Bartt RE. Statin-associated peripheral neuropathy: review of the literature. Pharmacotherapy 2004; 24:1194-1203.
20. Zhou L, Kitch DW, Evans SR, Hauer P, Raman S, Ebenezer GJ, et al. Correlates of epidermal nerve fiber densities in HIV-associated distal sensory polyneuropathy. Neurology 2007; 68:2113-2119.
21. Vercesi AE, Castilho RF, Kowaltowski AJ, Oliveira HC. Mito-chondrial energy metabolism and redox state in dyslipidemias. IUBMB Life 2007; 59:263-268.
22. Vincent AM, Russell JW, Low P, Feldman EL. Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr Rev 2004; 25:612-628.
23. Vincent AM, Hayes JM, McLean LL, Vivekanandan-Giri A, Pennathur S, Feldman EL. Dyslipidemia-induced neuropathy in mice: the role of oxLDL/LOX-1. Diabetes 2009; 58:2376-2385.
24. Wiggin TD, Sullivan KA, Pop-Busui R, Amato A, Sima AA, Feldman EL. Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes 2009; 58:1634-1640.
25. Ridker PM. Fasting versus nonfasting triglycerides and the prediction of cardiovascular risk: do we need to revisit the oral triglyceride tolerance test? Clin Chem 2008; 54:11-13.
26. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007; 298:309-316.
27. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366:1849-1861.